Li, Xi-Ya
Wu, Ji-Chuan
Liu, Ping
Li, Zi-Juan
Wang, Yong
Chen, Bing-Yi
Hu, Cheng-Long http://orcid.org/0000-0002-2928-2625
Fei, Ming-Yue http://orcid.org/0000-0002-7699-7842
Yu, Peng-Cheng
Jiang, Yi-Lun http://orcid.org/0000-0002-6010-9775
Xu, Chun-Hui http://orcid.org/0000-0002-3836-3179
Chang, Bin-He
Chen, Xin-Chi
Zong, Li-Juan
Zhang, Jia-Ying
Fang, Ying
Sun, Xiao-Jian http://orcid.org/0000-0001-8826-4614
Xue, Kai
Wang, Li
Chen, Shu-Bei
Jiang, Shi-Yu
Gui, Ai-ling
Yang, Ling
Gu, Juan J.
Yu, Bao-Hua
Zhang, Qun-ling http://orcid.org/0000-0003-2513-1667
Wang, Lan
Article History
Received: 30 April 2022
Revised: 19 October 2022
Accepted: 26 October 2022
First Online: 9 November 2022
Competing interests
: The authors declare no competing interests.
: Primary relapsed patient cells were obtained from puncture samples of consenting patients with chemotherapy or rituximab treatment failure. For the collection and use of samples, informed consent was obtained from all subjects. The approval number of committees for ethical review is 050432-4-1212B. All animal interventions were approved by the ethics committee. The approval number of committees for ethical review is SINH-2021-WL-3.